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rent 20%) in the population. CONCLUSIONS: The
model suggests that annual PSA screening of male popu-
lation for prostate cancer is extremely cost-effective,
given current data. Further research into outcomes of
prostate cancer is needed to estimate cost-effectiveness of
screening in various subpopulations. In particular, given
the long clinical progression of prostate cancer, more re-
search is required into outcomes and cost-effectiveness in
relatively healthy patients versus those burdened by seri-
ous co-morbidities.
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OBJECTIVES: To conduct an economic evaluation of an
open label, phase III randomized trial involving centers in
North America and Europe. METHODS: There were 239
and 235 patients in the liposomal doxorubicin (50mg/m2
every 4 weeks) and topotecan (1.5mg/m2 for 5 days every
3 weeks) arms, respectively. Overall median survival was
420 days and 397 days for liposomal doxorubicin and to-
potecan, respectively (hazard ratio  1.12 (90% CI
0.92,1.37; p  .34)). Because the outcomes were not clin-
ically different for the 2 groups, a cost minimization anal-
ysis was performed. Costs included were: study drug;
drug administration; and management of adverse events.
Actual mg of drug administered and frequency and sever-
ity of adverse events were obtained from the clinical trial.
Expert opinion was used to estimate the resources used in
the treating adverse events, and unit costs were based on
UK practice data. Further validation of the expert opinion
is currently underway. RESULTS: Severe (Grade III/IV)
toxicities were more frequent for liposomal doxorubicin
versus topotecan in terms of palmar-plantar erythrodyses-
thesia (PPE) (n  64 vs. 0), and stomatitis/pharyngitis (n 
32 vs. 2) but less frequent for thrombocytopenia (n  3
vs. 238), anemia (n  19 vs. 146), neutropenia (n  55
vs. 764) and fever (n  2 vs. 13). The average cost per pa-
tient was estimated to be EUR16,230 (95% CI 14,780 to
17,680) and EUR20,554 (95% CI 18,764 to 22,344) for
liposomal doxorubicin and topotecan, respectively. Per
patient cost for drug  administration were similar be-
tween the two groups, (EUR14,974 and EUR15,073); the
main differential in cost was management of anemia
(EUR407 and EUR2,219) and neutropenia (EUR57 and
EUR1,454) for the liposomal doxorubicin and topotecan
groups, respectively. CONCLUSIONS: In settings where
the current standard of care for platinum refractory or re-
sistant ovarian cancer is topotecan, liposomal doxorubi-
cin offers the potential for savings through reduction in
cost of adverse event management.
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Cost-utility analysis is rapidly becoming the standard
pharmacoeconomic measure in oncology. OBJECTIVE:
To compare paclitaxel (pac) and docetaxel (doc) in the
treatment of second line or greater metastatic breast can-
cer using a cost-utility analysis. METHODS: Utilities we
collected from 45 patients using eight modified Markov
modeled health states (Pharmacoeconomics, 1996;
60:504) describing metastatic breast cancer; the standard
gamble procedure was utilized to obtain utility. Costs
were collected prospectively from 31 patients in a single
outpatient center. Direct medical costs were collected
(e.g., all medications, physician/clinic/laboratory visits,
ER, hospitalizations, home health care, consultations,
special procedures, transfusions, phone calls, and miscel-
laneous) and costs were defined using Medicare reim-
bursement rates and AWP for drugs. Sensitivity analyses
are currently underway. RESULTS: The average cost per
cycle of chemotherapy was $4,298 and $2,869 for doc
and pac respectively. The mean utility score obtained
from patients was .78 and .76 for doc and pac respec-
tively. The utility scores suggest that doc offers 7.3 days
of perfect health when compared to pac. However, the
incremental cost-utility analysis (cost of doc  cost of
pac/QALY of doc  QALY of pac) indicates that the use
of doc costs $71,450 per Quality Adjusted Life Year
(QALY) when compared to pac. Another way to view
these results is that it costs $195.75 more per Quality Ad-
justed Day (QAD) to treat a patient with docetaxel.
CONCLUSIONS: Our results indicate that docetaxel is
more expensive ($4,298/cycle vs. $2,869/cycle) than pa-
clitaxel, and that metastatic breast cancer patients do not
perceive the drugs as being different (utility scores .76 for
pac and .78 for doc). This cost-utility analysis suggests
that the use of docetaxel over paclitaxel may not be justi-
fied in the treatment of metastatic breast cancer.
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OBJECTIVE: Chemotherapy-induced bone marrow tox-
icity is expensive because of the cost of managing compli-
cations of pancytopenia. Growth factors minimize these
complications. Economic analyses of growth factors typi-
cally focus on common, less serious outcomes, rather
